North America Pharmaceutical Market Size and Forecast by Offerings, Therapeutic Area, Route of Administration, and Distribution Channel: 2019-2034

Formulary Exclusion Constrains Biosimilar Access Despite FDA Approvals

Pharmacy benefit managers and commercial payers administering drug benefits across the United States and Canada operate formulary architectures that have increasingly diverged from the FDA's biosimilar approval output. The FDA has approved dozens of biosimilar entries across therapeutic categories including oncology, immunology, and endocrinology, yet dispensing penetration across many of those categories remains materially below what approval volumes alone would suggest. The more consequential structural constraint is not regulatory capacity — it is the rebate retention model that incentivizes pharmacy benefit managers to maintain originator biologics on preferred formulary tiers while placing approved biosimilars in higher cost-sharing positions or excluding them outright. This contracting architecture, rather than any insufficiency in the FDA's review process, now functions as the primary market access gate determining which biosimilar products reach patients at dispensing scale within the North America pharmaceutical sector.

The Inflation Reduction Act's drug price negotiation provisions, which the Centers for Medicare and Medicaid Services began implementing in 2024, have introduced a parallel pressure on manufacturer pricing calculus that intersects with the biosimilar access question in commercially significant ways. Originators subject to negotiated Medicare pricing have less revenue headroom to sustain the large formulary rebate volumes that historically displaced biosimilar competitors — a condition that may, over the 2026–2034 period, gradually alter the incentive calculus for pharmacy benefit managers when constructing preferred tier placements. Whether this rebalancing translates into measurable biosimilar substitution gains will depend at least in part on whether payer contracting practices adjust faster than manufacturers recalibrate exclusionary rebate structures, a dynamic that remains unresolved across the North America pharmaceutical market as of 2026.

Rebate Architecture: Formulary Placement as Access Barrier

The tiered formulary infrastructure administered by pharmacy benefit managers across the United States places FDA-approved biosimilars at a structural disadvantage that originates in contracting economics rather than clinical evidence. Rebate agreements between originator biologic manufacturers and benefit managers create financial incentives to assign lower cost-sharing tiers to reference products, directing patient volume away from biosimilar alternatives even when those alternatives carry equivalent therapeutic designations. Specialty pharmaceutical purchasers — including employer-sponsored health plans covering the largest commercially insured populations — face formulary designs where biosimilar preferred-tier placement is conditional on rebate competitiveness, a threshold that nascent biosimilar entrants frequently cannot meet at launch-year volumes. At least in part because of this contracting structure, FDA biosimilar approval in the North America pharmaceutical sector functions as a market entry credential rather than a dispensing guarantee, compressing the commercial return window that biosimilar developers depend upon to sustain pipeline investment.

Formulary Design Creates Biosimilar Formulary Optimization Openings

Unlike markets where public payer formularies set a uniform national access threshold, the United States operates a fragmented commercial formulary environment in which each pharmacy benefit manager independently negotiates tier placement with biologic and biosimilar manufacturers — producing access outcomes that diverge markedly across employer-sponsored plans covering comparable patient populations. The Inflation Reduction Act's Medicare drug price negotiation provisions, now active through the Centers for Medicare and Medicaid Services, have compressed originator revenue on high-spend biologics, reducing the rebate headroom that originators can offer benefit managers to retain preferred-tier status and creating a structural opening for formulary design consultants and biosimilar access platforms to reposition approved alternatives at commercially viable tiers. Vendors capable of modeling rebate-adjusted net cost comparisons across therapeutic categories — particularly in immunology and endocrinology, where biosimilar approval density is highest — can offer employer health plan sponsors the analytical infrastructure needed to capture formulary savings that the current rebate-driven architecture has systematically suppressed within the North America pharmaceutical sector.

Biosimilar Approval Volumes Outpace Formulary Dispensing Penetration

FDA biosimilar approvals accelerating across immunology and oncology have not translated into proportional dispensing penetration, marking a structural divergence between regulatory output and commercial access that became measurable once the Centers for Medicare and Medicaid Services began implementing the Inflation Reduction Act's negotiation provisions in 2024. The most direct observable indicator of this divergence is biosimilar market share as a proportion of total biologic dispensing volume within employer-sponsored commercial plans — a metric that, in rebate-intensive categories such as tumor necrosis factor inhibitors, has remained materially below approval-implied expectations. While the FDA's biosimilar designation pipeline has expanded substantially, pharmacy benefit manager formulary placement data indicates that originator biologics retain preferred-tier status across a majority of commercial plan designs, compressing biosimilar capture rates. This gap between regulatory approval density and actual dispensing share is likely to widen in therapeutic areas where rebate retention economics remain intact despite negotiation-driven originator revenue compression.

Rebate Retention Eroding Biosimilar Dispensing Viability

The federal framework governing Medicare drug price negotiation, administered by the Centers for Medicare and Medicaid Services under the Inflation Reduction Act, has compressed originator biologic revenue in negotiated categories without dismantling the rebate contracting architecture that pharmacy benefit managers use to sustain preferred-tier placement for those same reference products in commercial formularies. The mechanism producing this constraint is the structural decoupling between Medicare pricing outcomes and commercial plan formulary decisions — originator manufacturers facing negotiated Medicare prices have redirected rebate concentration toward commercial benefit manager contracts, reinforcing rather than loosening the cost-sharing penalty applied to FDA-approved biosimilar alternatives. Specialty biologic categories, particularly tumor necrosis factor inhibitor therapies where biosimilar approval density is high, experience the sharpest compression in dispensing viability, as nascent biosimilar entrants cannot match the rebate volumes needed to secure preferred commercial tier placement against originators defending remaining revenue streams. The more consequential outcome — given that commercial employer-sponsored plans represent the largest insured population in the North America pharmaceutical sector — is that biosimilar manufacturers face a market access architecture in which FDA approval confers no formulary protection, making launch-period revenue recovery structurally unpredictable.

North America Pharmaceutical Market Analysis By Country

United States: Rebate-driven formulary architecture and Medicare negotiation provisions structurally constrain biosimilar dispensing penetration across commercial employer-sponsored plans.

Canada: Provincial formulary fragmentation limits uniform biosimilar uptake, as pan-Canadian reimbursement alignment remains incomplete across publicly administered drug benefit programs.

Mexico: Segmented public procurement channels and limited specialty biologic reimbursement coverage restrict commercial market access for advanced therapeutic categories including biologics and biosimilars.

What North America's Formulary Architecture Reveals About Pharmaceutical Competition

Formulary tier positioning — not pipeline breadth alone — has emerged as the decisive competitive dimension across the North America pharmaceutical sector, where commercial payer contracts determine whether an approved product reaches dispensing volume or stalls at launch. Pfizer, AbbVie, Johnson & Johnson, Merck & Co., Eli Lilly, Amgen, and Gilead Sciences each compete across branded prescription drugs, biologics, oncology, immunology, OTC consumer health, and specialty categories, with their ability to negotiate preferred-tier placement inside employer-sponsored commercial formularies functioning as a parallel revenue gate alongside FDA approval status. The field also includes Teva Pharmaceutical, whose biosimilar portfolio spanning oncology, immunology, and ophthalmology positions it as a structurally distinct competitor whose commercial returns are directly determined by the formulary access conditions that originator manufacturers actively manage against it.

Across the competitive field, the dominant pattern has been pipeline acquisition as a mechanism for defending revenue against approaching patent cliffs. Johnson & Johnson's acquisition of Intra-Cellular Therapies added neuroscience assets to reinforce its specialty portfolio, while Gilead Sciences acquired full control of Arcellx's investigational cell therapy for multiple myeloma, and Merck & Co. absorbed Terns Pharmaceuticals to extend its oncology reach ahead of Keytruda's anticipated exclusivity loss. Eli Lilly, having generated substantial cash from its GLP-1 franchise, has deployed capital toward CNS through its Centessa Pharmaceuticals agreement. Biogen's acquisition of Apellis Pharmaceuticals expanded its immunology positioning. Royalty Pharma and Teva entered a funding agreement of up to $500 million to accelerate clinical development of Teva's anti-IL-15 antibody TEV-'408, illustrating how biosimilar-oriented players are simultaneously building innovative pipelines to reduce dependence on access-constrained product categories.

Competitive differentiation within the field increasingly separates players whose revenue architecture rests on originator rebate relationships from those whose returns depend on displacing those originators inside the same formulary. AbbVie, managing Humira biosimilar erosion while advancing Skyrizi and Rinvoq, operates within the rebate contracting system as an incumbent defending commercial tier placement; Teva and biosimilar-focused entrants operate against that same system, with formulary access outcomes determining whether their regulatory approvals convert to dispensing revenue. The more consequential competitive consequence of this bifurcation — given that formulary tier architecture has proven more durable than either regulatory or pricing pressure in redirecting patient volume — is that originator manufacturers holding rebate leverage with pharmacy benefit managers retain a structural commercial advantage that pipeline acquisition alone cannot neutralize for biosimilar competitors operating within the North America pharmaceutical sector.